Clinical trials
Epilepsy (Treatment Refractory) clinical trials
Below are recruiting epilepsy (treatment refractory) clinical trials, each written for real people, not researchers. We’re tracking 63 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07716930Enrolling by invitation
Eye scan study for drug-resistant epilepsy
This study uses a special eye scan (OCT) to look for changes in the retina that might be linked to hard-to-control epilepsy. The goal is to find new biomarkers that could help doctors better understand and manage the condition.
IstanbulAges 18–40 - NCT07110454Recruiting
Long-term follow-up study for epilepsy monitoring implant
This study follows people who previously enrolled in the DETECT study and had a Minder device implanted to monitor brain activity. The goal is to see how the device performs over a longer period of time.
Phoenix, ArizonaAges 18–75 - NCT05019885RecruitingPhase 2
IV ketamine for hard-to-treat epilepsy in adults
This Phase 2 study tests whether a low dose of IV ketamine can reduce seizures in adults with drug-resistant epilepsy. It may help people whose seizures continue despite trying at least two appropriate seizure medicines.
New York, New YorkAges 18 years+ - NCT07110337Recruiting
Diagnosing epilepsy to help guide treatment
This trial tests a new device to help diagnose epilepsy in people whose previous EEG brain monitoring did not give clear answers. If you have drug-resistant epilepsy with at least one seizure a month on average, this study may help find better treatment options.
Phoenix, ArizonaAges 18–75 - NCT07095933RecruitingEarly Phase 1
Everolimus for hard-to-control focal epilepsy
This study tests whether the medicine everolimus (taken as a pill) can safely reduce seizures in adults with focal epilepsy that hasn't been controlled by other treatments. You would continue your current seizure medicines and add everolimus.
Beijing, Beijing MunicipalityAges 18–60 - NCT07680842Recruiting
Non-invasive ultrasound for drug-resistant epilepsy
This study tests a non-invasive focused ultrasound treatment for people with epilepsy that doesn't respond to medications. The goal is to see if this gentle ultrasound can reduce seizures without surgery.
San Francisco, CaliforniaAges 21–65 - NCT07668856RecruitingPhase 3
CBD for children with hard-to-treat epilepsy
This trial tests if adding cannabidiol (CBD) to your child's current seizure medicines can reduce seizures. It uses a personalized approach to see if CBD works for each child.
Utrecht, UtrechtAges 1–18 - NCT07378397Enrolling by invitation
MEG brain mapping for epilepsy surgery in children
This study uses a safe brain scan (MEG) to help doctors plan epilepsy surgery for children. It aims to make surgery safer and more precise by mapping key brain areas beforehand.
Birmingham, United KingdomAges 6–15 - NCT07353918Enrolling by invitation
Focused ultrasound for epilepsy treatment
This study tests if low-intensity focused ultrasound can calm overactive brain areas in people with epilepsy. It may offer a new way to reduce seizures without surgery or strong medications.
Roanoke, VirginiaAges 18–85 - NCT06719791RecruitingEarly Phase 1
Sirolimus for hard-to-treat focal epilepsy
This trial tests if the drug sirolimus can help people with focal seizures (starting in one part of the brain) that don't improve with at least two other medications. It aims to reduce seizure frequency in adults aged 18 to 60.
BeijingAges 18–60 - NCT06952764Enrolling by invitation
ECLIPSE: Tracking epilepsy cycles to predict seizures
This trial tests if tracking your brain activity with an implanted device can help predict when seizures might happen. It is for adults who have seizures despite medication and already have the RNS System implanted.
San Francisco, CaliforniaAges 18 years+ - NCT06863350Recruiting
Closing a heart hole to treat drug-resistant epilepsy
This trial tests if closing a small hole in the heart (called a PFO) can reduce seizures in people whose epilepsy isn't controlled by medication. It might offer a new treatment option for those who have both drug-resistant epilepsy and this heart condition.
Chengdu, SichuanAges 18–60 - NCT05845255Recruiting
Test wearable monitoring for epilepsy quality of life and safety
This study tests a wearable device that records seizure-related information to understand how epilepsy affects daily life and safety. It may help your care team better track seizures in real-world settings and understand quality-of-life changes.
KorkAges 12–65 - NCT06762743Enrolling by invitationPhase 1
Comparing two brivaracetam oral solutions in healthy adults
This study tests whether two different forms of an oral solution of brivaracetam (a seizure medication) have the same effect in the body. Healthy adults take one dose and have blood samples collected—first on an empty stomach, and later after a high-fat meal—to compare how the drug is absorbed.
Nanjing, JiangsuAges 18–55 - NCT07219407RecruitingPhase 2
Long-term safety study of RAP-219 for focal seizures
This study tests the long-term safety and effectiveness of RAP-219, an investigative medication for focal epilepsy. It is for people who already completed an earlier study of RAP-219, have a type of epilepsy that doesn't respond to standard medicines, and use a surgically implanted brain device (RNS system) to help manage seizures.
Boise, IdahoAges 18–70 - NCT06292494Recruiting
Focused ultrasound for drug-resistant epilepsy
This trial tests whether focused ultrasound can help people whose seizures are not controlled by two or more medications. You would have a noninvasive procedure while awake, pressing a stop button if needed, and your hair will be partially shaved.
TaipeiAges 18 years+ - NCT07266181RecruitingPhase 1
CAR-T cell therapy for tough-to-treat membranous nephropathy
This trial tests whether specially engineered immune cells (CAR-T cells) can help people with a kidney condition called primary membranous nephropathy that has not improved with standard treatments. The goal is to see if this therapy can reduce protein in the urine and protect kidney function.
Xi'an, ChinaAges 18 years+ - NCT07403266RecruitingPhase 3
Full-spectrum cannabis oil for seizures in tuberous sclerosis
This trial tests a full-spectrum cannabis extract to see if it reduces seizures in people with tuberous sclerosis complex (TSC) whose seizures have not been controlled by other treatments. If it works, it could offer a new option for managing hard-to-treat epilepsy.
MadridAges 2–65 - NCT06132893RecruitingPhase 2/Phase 3
Testing BHV-7000 for hard-to-control focal seizures in adults
This study tests a new medicine called BHV-7000 for adults whose focal seizures (starting in one part of the brain) are not controlled by current treatments. The goal is to see if it can reduce seizures safely.
Phoenix, ArizonaAges 18–75 - NCT02151175Enrolling by invitation
Focused ultrasound to treat medication-resistant temporal lobe seizures
This trial tests a low-intensity focused ultrasound treatment aimed at reducing seizures caused by problems in one side of the hippocampus (a brain area involved in memory and seizures). It’s for people whose seizures have not responded to several seizure medicines and who have been offered a specific type of surgery.
Los Angeles, CaliforniaAges 18–60 - NCT06787989RecruitingPhase 1
BCMA-CD19 car T cell therapy for immune thrombocytopenia with autoimmune diseases
This trial tests a personalized cell therapy (CAR T cells) that targets two proteins (BCMA and CD19) on immune cells to treat low platelet counts (thrombocytopenia) that haven't improved with other treatments and are linked to autoimmune diseases like lupus or Sjogren's. The goal is to see if this therapy can safely raise your platelet levels and reduce bleeding symptoms.
Chengdu, SichuanAges 18–60 - NCT05327387Recruiting
Brain stimulation study using implanted electrodes
This study tests a model-based way of using electrical brain stimulation in people who are having surgery for drug-resistant epilepsy or brain tumors. It uses implanted electrodes to measure brain activity and may help improve how stimulation is planned during surgical care.
Los Angeles, CaliforniaAges 18 years+ - NCT05254730Recruiting
Testing brain-recording sensors to map the seizure source
This study looks at using special tiny filaments during brain monitoring to better identify where seizures start. It’s meant for people with hard-to-control (refractory) epilepsy who are already being considered for a specific brain-monitoring procedure.
Montreal, QuebecAges Any age - NCT06973512Recruiting
Brain stimulation for severe addiction
This trial tests a new brain stimulation approach for people with severe addiction that hasn't gotten better with other treatments. It uses deep brain stimulation guided by brain mapping to try to reduce cravings and help you stay abstinent.
Toronto, OntarioAges 25–65
Hear when a new Epilepsy (Treatment Refractory) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Epilepsy (Treatment Refractory) trials by city
Studies with a site in or near these metro areas.
Epilepsy (Treatment Refractory) trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for epilepsy (treatment refractory)?
- Yes. Clin2 currently lists 63 recruiting epilepsy (treatment refractory) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a epilepsy (treatment refractory) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a epilepsy (treatment refractory) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.